Approved HIV Drugs
Approved HIV Drugs
FDA Approves Juluca Dual Single-Tablet Regimen
- Details
- Category: Approved HIV Drugs
- Published on Thursday, 30 November 2017 00:00
- Written by HIVandHepatitis.com
On November 21, the U.S. Food and Drug Administration approved Juluca, a fixed-dose coformulation containing dolutegravir and rilpivirine, for the treatment of adults with HIV who have undetectable viral load on their current antiretroviral regimen. Juluca, a joint product of ViiV Healthcare and Janssen, is the first complete single-tablet regimen containing only 2 drugs.
HIV Glasgow: Darunavir/Ritonavir + Lamivudine Matches Triple-Drug HIV Therapy
- Details
- Category: Approved HIV Drugs
- Published on Monday, 07 November 2016 00:00
- Written by Keith Alcorn
Simplifying antiretroviral therapy to a 2-drug combination of lamivudine plus the protease inhibitor darunavir (Prezista) boosted by ritonavir is just as effective as a 3-drug regimen in people with suppressed viral load, Spanish investigators reported at the International Congress on Drug Therapy in HIV infection (HIV Glasgow) last month in Glasgow.
IDWeek 2016: Omega-3 Fatty Acids May Improve Triglycerides and Inflammation in HIV+ People
- Details
- Category: Approved HIV Drugs
- Published on Sunday, 06 November 2016 00:00
- Written by Liz Highleyman
Long-term use of omega-3 fatty acid supplements was associated with reduced levels of triglycerides and the inflammation biomarker C-reactive protein (CRP) in HIV-positive people with suppressed viral load, according to research presented last week at IDWeek 2016 in New Orleans.
IDWeek 2016: Tenofovir Alafenamide Works Well and Improves Kidney and Bone Markers in Older HIV Patients
- Details
- Category: Approved HIV Drugs
- Published on Sunday, 06 November 2016 00:00
- Written by Liz Highleyman
A coformulation of tenofovir alafenamide (TAF) plus emtricitabine, used with a third antiretroviral drug, maintained viral suppression as well as tenofovir disoproxil fumarate (TDF) plus emtricitabine in older individuals, and was associated with improvements in kidney function and bone density, which may be of greater concern for this group, according to a presentation last week at IDWeek 2106 in New Orleans.
IDWeek 2016: Dolutegravir Regimen Works Better than Atazanavir in Clinical Trial for Women
- Details
- Category: Approved HIV Drugs
- Published on Monday, 31 October 2016 00:00
- Written by Liz Highleyman
A once-daily regimen containing the potent HIV integrase inhibitor dolutegravir worked better than an older atazanavir-containing regimen -- with higher rates of viral suppression both overall and across race subgroups -- in the ARIA trial, one of the few antiretroviral therapy studies to enroll only women, according to a presentation at IDWeek last week in New Orleans.
More Articles...
- HIV Glasgow: Dolutegravir and Central Nervous System Side-Effects -- Abacavir, Older Age Increase the Risk
- Genvoya TAF Regimen Works Well with Improved Bone and Kidney Safety at 96 Weeks
- Tenofovir Resistance May Develop in More than Half of Patients Failing Treatment
- 6. New TAF Version of Tenofovir Approved in Combo Pill
Web Design and Development by